About US
Contact us
-
ATMI Announces Agreement to Sell LifeScienc​es Business to Pall Corporatio​nATMI, Inc., a global technology company and leader in single-use bioprocess solutions, has reached agreement with Pall Corporation to sell ATMI LifeSciences in a transaction valued at $185 million.2013/12/26
-
Novo gets a year-end win for Factor XIII blood-clotting product after two rejectionsThree's a charm for Novo Nordisk ($NVO) and its recombinant Factor XIII compound for a rare bleeding disorder. After receiving a complete response letter (CRL) in 2012 and then again this August, the2013/12/26
-
FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia A&B patients with inhibitorsThe US Food and Drug Administration (FDA) has approved Baxter's FEIBA [anti-inhibitor coagulant complex] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A2013/12/25
-
FDA Approves Tretten to Treat Rare Genetic Clotting Disorder‏FDA hasapproved Tretten, Coagulation Factor XIII A-Subunit (Recombinant), the first recombinant product for use in the routine prevention of bleeding in adults and children who have a rare clotting di2013/12/25
-
Takeda acquires exclusive rights to develop Natrogen's anti-inflammatory compoundTakeda Pharmaceutical has entered into an exclusive licence and option agreement with Natrogen Therapeutics International. The licensing is for the development of Natrogen's Natura-alpha compound for2013/12/24
-
FDA Requires Multiple New Safety Measures for Leukemia Drug Iclusig; Company Expected to Resume Marketing‏FDA is requiring several new safety measures for the leukemia drug Iclusig (ponatinib) to address the risk of life-threatening blood clots and severe narrowing of blood vessels. Once these new safety2013/12/24
-
Acute Ischemic Stroke: Global Market Value to Grow Significantly by 2017, but Clinical Trial Challenges RemainThe acute ischemic stroke (AIS) therapeutics market in the six major countries — the US, France, Germany, Italy, Spain and UK — is forecast to jump from $531 million in 2012 to $1.2 billion by 2017, a2013/12/23
-
Molecular Profiles Joins Leading Consortium to Drive Paediatric Formulation DevelopmentA collaborative pharmaceutical project focused on improving the pathway for developing paediatric formulations has been given the go-ahead after successfully securing an innovation grant. The UK-wi2013/12/23
-
Merck and CNIO sign licence agreement for development of new cancer drugsMerck's biopharmaceutical division Merck Serono and the Spanish National Cancer Research Centre (CNIO) have signed an agreement in Madrid to collaborate in the developing of cancer drugs. This global2013/12/20
-
FDA Endorses, Pushes for Abuse-Resistant Opioid Formulations: Transition to Disrupt Pain MarketThe opioid market is dominated by non-tamper resistant formulations (TRFs), but the Food and Drug Administration’s (FDA’s) promotion of TRF therapies could well result in the departure of non-TRF ther2013/12/20